A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (NIH) (K01 CA184388-02)
- National Cancer Institute of the NIH (P30CA033572)
This publication has 57 references indexed in Scilit:
- The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirusNature Medicine, 2012
- Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: Maintenance of tight latency with efficient reactivation upon inductionJournal of Virological Methods, 2011
- Fusing structure and function: a structural view of the herpesvirus entry machineryNature Reviews Microbiology, 2011
- An Interleukin‐6–Related Systemic Inflammatory Syndrome in Patients Co‐Infected with Kaposi Sarcoma–Associated Herpesvirus and HIV but without Multicentric Castleman DiseaseClinical Infectious Diseases, 2010
- Correlates of Protection Induced by VaccinationClinical and Vaccine Immunology, 2010
- The IC50 of anti-Pfs25 antibody in membrane-feeding assay varies among speciesVaccine, 2010
- Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C VirusJournal of Virology, 2009
- Early Childhood Infection by Human Herpesvirus 8 in Zambia and the Role of Human Immunodeficiency Virus Type 1 Coinfection in a Highly Endemic AreaAmerican Journal of Epidemiology, 2008
- Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor SignalingScience, 2006
- Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's SarcomaScience, 1994